Abstract
131I-Labeled m-iodobenzylguanidine (131I-mIBG) was first synthesized by Wieland and co-workers1 and soon became widely used for diagnosis of neural crest tumors, such as pheochromocytoma2 and neuroblastoma.3 Because of I-123’s superior physical properties for scintigraphic imaging compared to I-131,4 123I-mIBG has become the preferred agent for diagnosis, staging, and clinical follow-up of patients with these tumors. In addition, 123I-mIBG has shown potential for cardiac applications, such as determination of regional myocardial adrenergic activity following myocardial infarctions5 and prioritization of candidates for heart transplantation.6
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wieland, D.M., Wu, J.-I., Brown, L.E., Mangner, T.J., Swanson, D.P., and Beierwaltes, W.H. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J. Nucl. Med. 21:349–353(1980).
Shapiro, B., Copp, J.E., Sisson, J.C., Eyre, P.L., Wallis, J., and Beierwaltes, W.H. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytomas: Experience in 400 cases. J. Nucl. Med. 26: 576–585 (1985).
Munkner, T. 131I-Meta-iodobenzylguanidine scintigraphy of neuroblastomas. Semin. Nucl. Med. 15:154–160(1985).
Home, T., Hawkins, L.A., Britton, K.E., Granowska, M., Bouloux, P. and Besser, G. M. Imaging of phaeochromocytoma and adrenal medulla with 123I-meta-iodobenzyl guanidine. Nucl. Med. Commun. 5:763–768 (1984).
McGhie, A.I., Corbett, J.R., Akers, M.S., Kulkarni, P., Sills, M.N., Kremers, M., Buja, L.M., Durant-Reville, M., Parkey, R.W., and Willerson, J.T. Regional cardiac adrenergic function using 1–123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction. A.M. J. Cardiol. 67:236–242 (1991).
Merlet, P., Valette, H., Dubois-Randè, J.-L., Moyse, D., Duboc, D., Dove, P., Bourguignon, M.H., Benvenuti, C., Duval, A.M., Agostini, D., Loisance, D., Castaigne, A., and Syrota, A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J. Nucl. Med. 33:471–477 (1992).
Paltiel, H.J., Gelfand, M.J., Elgazzar, A.H., Washburn, L.C., Harris, R.E., Masters, P.R., and Golsch, G.J. 1–123 MIBG imaging of neural crest tumors in children. Radiology (submitted).
Gelfand, M.J., Paltiel, HJ., Elgazzar, A.H., Washburn, L.C., Williams, C.C., Harris, R.E., Masters, P.R., and Maxon, H.R. I-123-MIBG imaging of neural crest tumors. J. Nucl. Med. 33:1072 (1992) (abstract).
Mock, B.H. and Weiner, R.E. Simplified solid-state labeling of [123I]m-iodobenzyl-guanidine. Appl. Radiat. Isot. 39:939–942 (1988).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Washburn, L.C., Khosla, R.C., Williams, C.C., Gelfand, M.J., Maxon, H.R. (1995). Production and Application of 123I-Labeled M-Iodobenzylguanidine (123I-MIBG). In: Emran, A.M. (eds) Chemists’ Views of Imaging Centers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9670-4_32
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9670-4_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9672-8
Online ISBN: 978-1-4757-9670-4
eBook Packages: Springer Book Archive